{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:25Z","timestamp":1787004865060,"version":"build-2736575974"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>A long history of policymaking and regulation constructed for the purpose of ensuring adequate fetal and infant protections has inadvertently sanctioned the widespread exclusion of pregnant and lactating patients from biomedical research, leaving a paucity of high quality data necessary for clinical decision-making. Although well-intended, the regulatory classification of pregnant women as \u201cvulnerable,\u201d in conjunction with burdensome enrollment criteria and other factors weighing against broad inclusion, have ultimately placed the health and safety of these women and their babies in jeopardy. Robust measures are urgently needed to overcome patient and physician reluctance, address substantial evidence gaps, and rectify long-standing disparities which precipitate disproportionately poor health outcomes among this population. In February 2023, the Advancing Safe Medications for Moms and Babies Act of 2023 (the Act) was introduced in the United States House of Representatives with the overarching goal of enabling pregnant and lactating women to achieve equitable participation in clinical research and contribute to developing important biomedical knowledge to guide and improve health care delivered to these patients. This review discusses the historical influence of federal human subject protection regulations on the health and clinical treatment of pregnant and lactating women, outlines and critically analyzes the provisions incorporated into the Act, and reflects on the potential long-term impact the Act would have should it be successful in becoming law.<\/jats:p>\n                  <jats:p>Key Points<\/jats:p>","DOI":"10.1055\/a-2308-3580","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T18:59:37Z","timestamp":1713380377000},"page":"139-146","source":"Crossref","is-referenced-by-count":1,"title":["Equitable Representation of Pregnant and Lactating Women in Clinical Research: A Historical Review and Critical Analysis of Proposed Legislation"],"prefix":"10.1055","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-9105","authenticated-orcid":false,"given":"Richard H.","family":"Woods","sequence":"additional","affiliation":[{"name":"Levin, Papantonio, Rafferty, Proctor, Buchanan, O'Brien, Barr & Mougey, P.A., Pensacola, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt.676","article-title":"Evaluation of the safety of drugs and biological products used during lactation: workshop summary","volume":"101","author":"J Wang","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"01","key":"ref3","first-page":"1","article-title":"Births: final data for 2021","volume":"72","author":"M JK Osterman","year":"2023","journal-title":"Natl Vital Stat Rep"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","article-title":"The second wave: toward responsible inclusion of pregnant women in research","volume":"1","author":"A D Lyerly","year":"2008","journal-title":"Int J Fem Approaches Bioeth"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.addr.2020.09.013","article-title":"Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies","volume":"170","author":"K M Nelson","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1111\/bcp.14649","article-title":"Drug therapy during pregnancy","volume":"88","author":"D Sun","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajmg.c.30313","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","author":"M P Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"A A Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.semperi.2015.08.002","article-title":"Epidemiology of medications use in pregnancy","volume":"39","author":"M Ayad","year":"2015","journal-title":"Semin Perinatol"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0037-1598070","article-title":"Improving safe and effective use of drugs in pregnancy and lactation: workshop summary","volume":"34","author":"L E Riley","year":"2017","journal-title":"Am J Perinatol"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/AOG.0000000000002579","article-title":"Prescription and other medication use in pregnancy","volume":"131","author":"D M Haas","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/bfm.2007.0010","article-title":"Extent of medication use in breastfeeding women","volume":"2","author":"E E Stultz","year":"2007","journal-title":"Breastfeed Med"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0890334418775630","article-title":"Medication use during pregnancy and lactation in a Dutch population","volume":"35","author":"M de Waard","year":"2019","journal-title":"J Hum Lact"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1073110520917030","article-title":"There oughta be a law: when does(n't) the U.S. Common Rule apply?","volume":"48","author":"M N Meyer","year":"2020","journal-title":"J Law Med Ethics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1073110520917032","article-title":"Mobile research applications and state research laws","volume":"48","author":"S A Tovino","year":"2020","journal-title":"J Law Med Ethics"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.whi.2012.10.003","article-title":"Enrolling pregnant women: issues in clinical research","volume":"23","author":"M C Blehar","year":"2013","journal-title":"Womens Health Issues"},{"key":"ref31","volume-title":"Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies","author":"Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies","year":"1994"},{"issue":"9715","key":"ref32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(10)60257-7","article-title":"Enrolling pregnant women in biomedical research","volume":"375","author":"R Macklin","year":"2010","journal-title":"Lancet"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-017-2402-9","article-title":"Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach","volume":"19","author":"R van der Graaf","year":"2018","journal-title":"Trials"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/add.13789","article-title":"Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network","volume":"112","author":"R Susukida","year":"2017","journal-title":"Addiction"},{"issue":"13","key":"ref35","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials","volume":"125","author":"E Hariton","year":"2018","journal-title":"BJOG"},{"issue":"9453","key":"ref36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"P M Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"e2015094","DOI":"10.1001\/jamanetworkopen.2020.15094","article-title":"Evaluation of drug labels following the 2015 pregnancy and lactation labeling rule","volume":"3","author":"J J Byrne","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/pds.3410","article-title":"Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011","volume":"22","author":"S L Peters","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S146091","article-title":"Risks versus benefits of medication use during pregnancy: what do women perceive?","volume":"12","author":"B Mulder","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fpubh.2020.00028","article-title":"Beliefs and risk awareness on medications among pregnant women attending the antenatal care unit in Ethiopia University Hospital. Overestimating the risks is another dread","volume":"8","author":"Y G Tefera","year":"2020","journal-title":"Front Public Health"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","article-title":"Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review","volume":"3","author":"A S Tahhan","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"e015594","DOI":"10.1161\/JAHA.119.015594","article-title":"Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs","volume":"9","author":"M S Khan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref51","first-page":"100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"B E Turner","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMhle1901265","article-title":"Promoting pediatric drug research and labeling - outcomes of legislation","volume":"381","author":"F T Bourgeois","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","article-title":"Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act","volume":"173","author":"T J Hwang","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1542\/peds.2010-2585","article-title":"Pediatric drug-trial recruitment: enticement without coercion","volume":"127","author":"C L Tishler","year":"2011","journal-title":"Pediatrics"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2125.2009.03561.x","article-title":"Promoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign","volume":"69","author":"I S Mackenzie","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/2168479013478953","article-title":"Impact of in-pharmacy education on patients' knowledge and attitudes about clinical trials","volume":"47","author":"K A Getz","year":"2013","journal-title":"Ther Innov Regul Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1093\/cid\/ciu726","article-title":"Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices","volume":"59","author":"P M Frew","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"09","key":"ref59","doi-asserted-by":"crossref","first-page":"e2127792","DOI":"10.1001\/jamanetworkopen.2021.27792","article-title":"Demographic and health behavior factors associated with clinical trial invitation and participation in the United States","volume":"4","author":"C P Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacbts.2017.11.007","article-title":"Expanding patient access to investigational drugs: single patient investigational new drug and the \u201cRight to Try\u201d","volume":"3","author":"G A Van Norman","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"ref62","first-page":"127","article-title":"The effect of reminder systems on patients' adherence to treatment","volume":"6","author":"S D Fenerty","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"796590","DOI":"10.1155\/2012\/796590","article-title":"Adherence with drug therapy in pregnancy","volume":"2012","author":"D Matsui","year":"2012","journal-title":"Obstet Gynecol Int"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1177\/1049732318773724","article-title":"Clinical research with pregnant women: perspectives of pregnant women, health care providers, and researchers","volume":"28","author":"K Wada","year":"2018","journal-title":"Qual Health Res"},{"issue":"18","key":"ref65","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2023.21294","article-title":"Addressing the public health crisis of maternal mortality: a national research agenda","volume":"330","author":"D W Bianchi","year":"2023","journal-title":"JAMA"},{"key":"ref67","volume-title":"Maternal mortality rates in the United States, 2021","author":"D L Hoyert"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hast.1472","article-title":"Legal discrepancies and expectations of women: abortion, fetal therapy, and NICU care","volume":"53","author":"N Scheinerman","year":"2023","journal-title":"Hastings Cent Rep"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2308-3580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:57:59Z","timestamp":1735671479000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2308-3580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":42,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2308-3580","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,17]]},"published":{"date-parts":[[2024,4,17]]}}}